NF-κB和EGFR在不同放射敏感性胶质瘤中的表达

 目的 探讨NF-κB和EGFR的表达水平与胶质瘤放射敏感性的关系。方法 应用免疫组织化学SABC法检测NF-κB p50、p65及EGFR在5例正常脑组织和82例不同放射敏感性胶质瘤中的表达。结果 NF-κBB p50、p65和EGFR在正常脑组织中均未见表达。髓母细胞瘤、室管膜瘤、少枝胶质细胞瘤、低(Ⅰ～Ⅱ级)及高级别(Ⅲ～Ⅳ级)星形细胞瘤、多形性胶质母细胞瘤的NF-κB和EGFR表达率呈依次上升趋势。对放疗最敏感的髓母细胞瘤表达率与其他各组均有显著性差异(P<0．05)。结论 NF-κB和EGFR表达水平与胶质瘤的不同放射敏感性可能相关。     

LRIC1基因在人星形细胞瘤中的表达与意义(英文)

目的 LRIG1基因是新发现的与果蝇 Kek-1基因同源的人类基因。Kek-1基因编码一种果蝇细胞表面蛋白—kekkon-1蛋白,它可抑制果蝇表皮细胞生长因子受体(EGFR)介导的信号转导。人类 LRIG1蛋白是一种跨膜糖蛋白,胞外区含亮氨酸重复区域和免疫球蛋白样区域。既往的研究显示 LRIG1几乎表达在所有被检测的人类组织中,如前列腺、乳腺、回肠、胃、肺和脑组织等。然而,目前对它在人类组织中的作用仍然未知。本研究的目的是进一步扩大 LRIG1的表达谱,并探讨它在肿瘤中的作用与意义。方法设计、制作 LRIG1 mRNA 寡核苷酸探针,用原位杂交检测 LRIG1 mRNA 在16例不同级别人星形细胞瘤中的表达,并与相应的肿瘤周边组织相比较;原代培养11例星形细胞瘤细胞,用 PCNA 行免疫组化及 LRIG1探针行原位杂交,分析培养细胞 PCNA 表达和 LRIG1表达之间的关系。结果人星形细胞瘤与其周边组织中均有一定程度的 LRIG1表达,肿瘤组织表达 LRIG1的水平较肿瘤周边组织低,这种降低的程度与肿瘤的级别成正比;培养细胞中也有一定程度的 LRIG1表达,其表达的程度与 PCNA 染色呈反比。结论 LRIG1蛋白具有抑制星形细胞瘤生长或增殖的作用,LRIG1的表达下调,可能参与了肿瘤的发生和发展过程。     

婴儿双歧杆菌/胞嘧啶脱氨酶肿瘤靶向性基因治疗系统的构建(英文)

目的构建婴儿双歧杆菌/胞嘧啶脱氨酶靶向性基因治疗系统。方法 PCR 扩增 CD 基因,EcoR Ⅰ,BamH Ⅰ对 CD 基因和 pGEX-1LamdaT 质粒同时进行双酶切,获得4.9 kb、1.3 kh 两个 DNA 片段。T4 DNA 连接酶连接这两个片段构建重组的CD/pGEX-1LamdaT 质粒,然后用电穿孔法将重组质粒转染婴儿双歧杆菌。从阳性转染的婴儿双歧杆菌中提取重组质粒,双酶切后检测切取片段长度,采用 Sanger 双脱氧链终止法对提取的重组质粒中的插入片段进行测序。结果从阳性转染的婴儿双歧杆菌中获得了6.2 kb大小的重组质粒,该质粒经双酶切后,得到了4.9 kb 和1.3 kb 两个长度的片段,其长度分别与 pGEX-1LambdaT 及 CD 基因的长度相同。测序结果显示,提取的重组质粒中插入的基因片段全长及核苷酸序列与 CD 基因完全相同。结论外源性 CD 基因被准确插入 pGEX-1LambdaT 质粒并转入婴儿双歧杆菌中,婴儿双歧杆菌/胞嘧啶脱氨酶靶向性基因治疗系统被成功构建。     

前外侧或外侧硬脑膜外入路切除海绵窦区肿瘤：附9例临床经验

背景与目的：目前对海绵窦区肿瘤的手术治疗仍是神经外科的难题之一。本文旨在提高海绵窦区肿瘤的全切率，降低神经功能的残障率。方法：针对海绵窦外侧壁的显微解剖特点，结合典型病例分析，回顾性总结了9例海绵窦内肿瘤，经前外侧或外侧硬膜外入路，通过显微神经外科技术切开海绵窦外侧壁夹层，按神经走行方向切开，辨认肿瘤生长和颅神经的关系分块切除肿瘤。结果：9例海绵窦内肿瘤中，海绵状血管瘤1例，神经鞘瘤6例，脑膜瘤2例。全切除5例，3例次全切除，1例大部分切除。3例出现新的颅神经功能障碍症状，6个月后新出现的颅神经功能障碍症状减轻2例．完全恢复1例。结论：明确的海绵窦区显微外科解剖概念．娴熟的显微神经外科技术以及选择适当的手术入路是提高海绵窦区肿瘤的全切率，降低术中出血、术后残障率的关键因素。     

"APONEUROTIC SYSTEM" IN MEDICAL CLASSIC THE YELLOW EMPEROR''''S CANON OF INTERN AL MEDICINE IS THE EARLIEST DESCRIPTION ON NERVOUS SYSTEM IN HUMAN HI STORY

IntraditionalChinesemedicine(TCM),the channel(meridian)collateralsystemisclassifiedas channel,collateral,“Jingjin”(经筋aponeuroticsys temormusclesortendinomuscularstructuresalong thetwelveregularchannels)anddermalpart,etc.;accordingtothedifferentdistributionofthesystemin thehumanbody,itisspecificallydividedintotwelve regularchannels,twelvebranchesofregularmeridi ans,eightextrachannels,collaterals,fifteenmajor collaterals,minutechannels,minutecollaterals,su perficialcollaterals,“Jingjin”,a…     

针刺治疗脑外伤后抑郁症临床观察

目的:观察针刺治疗脑外伤后抑郁症的疗效.方法:针刺与口服抗抑郁药进行对照研究.结果:治疗组对照组有显著差异(P＜0.05).结论:提示针刺治疗脑外伤后抑郁症有良好的疗效.     

昆明山海棠胶囊对小鼠的生殖毒性研究

目的：探讨昆明山海棠胶囊的生殖系统毒性.方法：根据卫生部《中药新药研究指南》,进行该制剂的特殊毒理实验研究.结果：显性致死试验阳性;雌鼠均不能受孕;精子畸形率显著增高,随剂量增加而精子畸形率增高;对孕鼠重量、活胎重量及平均胎仔数等各项指标均无影响.结论：昆明山海棠胶囊具有低-中度的遗传毒性和一般生殖毒性,而无胚胎毒性.     

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

PURPOSE: To determine the maximum-tolerated dose (MTD), toxicities, and clinical effect of tipifarnib, a farnesyltransferase (FTase) inhibitor, in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs). This study compares the pharmacokinetics and pharmacodynamics of tipifarnib at MTD in patients on and off EIAEDs. PATIENTS AND METHODS: Recurrent malignant glioma patients were treated with tipifarnib using an interpatient dose-escalation scheme. Pharmacokinetics and pharmacodynamics were assessed. RESULTS: Twenty-three assessable patients taking EIAEDs received tipifarnib in escalating doses from 300 to 700 mg bid for 21 of 28 days. The dose-limiting toxicity was rash, and the MTD was 600 mg bid. There were significant differences in pharmacokinetic parameters at 300 mg bid between patients on and not on EIAEDs. When patients on EIAEDs and not on EIAEDs were treated at MTD (600 and 300 mg bid, respectively), the area under the plasma concentration-time curve (AUC)(0-12 hours) was approximately two-fold lower in patients on EIAEDs. Farnesyltransferase inhibition was noted at all tipifarnib dose levels, as measured in peripheral-blood mononuclear cells (PBMC). CONCLUSION: Toxicities and pharmacokinetics differ significantly when comparing patients on or off EIAEDs. EIAEDs significantly decreased the maximum concentration, AUC(0-12 hours), and predose trough concentrations of tipifarnib. Even in the presence of EIAEDs, the levels of tipifarnib were still sufficient to potently inhibit FTase activity in patient PBMCs. The relevance of these important findings to clinical activity will be determined in ongoing studies with larger numbers of patients.     

塞来昔布对人鼻咽癌CNE-2细胞生长抑制及放射增敏研究

Objective To investigate the growth inhibition and radiosensitization of Celecoxib in hu-man nasopharyngeal carcinoma cell line CNE-2. Methods CNE-2 growth inhibition by Celecoxib was eval-uated by MTT method. Apoptosis-related changes in morphology were observed by transmission electron mi-croscopy (TEM). Cell cycle distribution and apoptosis rate were measured by flowcytometry (FCM). The ex-pression of COX-2 protein was observed by SP method after the treatment of Celecoxib. Cells were randomly planted into four groups: irradiation control(Ci), drug group(Cd), irradiation group(R), and Celecoxib plus irradiation group(D+R). Single irradiation of 2,4,6,8,and 10 Gy were administered for colonogenic assay. Cell cycle distribution and apoptosis rate were analyzed at 6 Gy irradiation. Results The growth of CNE-2 cell was inhibited by celecoxib in a dose-and time-dependent manner, the IC50 was 80 μmol/L After the treatment, cell ratio of GO and G, phases was increased (47.03±2.76 vs 56.17±1.95, t=4.68, P= 0.010), whereas the ratio of S and G2/M phases was decreased (33.07±1.86 vs 24.87±1.76, t=5.54, P = 0.010; 19.30±0.53: 17.73±0.83, t=2.75, P=0.050), and the apoptosis rate was increased (1.57±0.47:10.47±0.31, t = 27.39, P = 0.000) in a dose-dependent manner. Apoptosis with nuclear chromatin condensation, fragmentation and cell shrinkage was found by TEM. SP method showed that Celeib decreased COX-2 expression (17.48±0.34 vs 12.82±0.51,t=13.20,P =0.00). The sensitivity ratio(D0) was 1.15. FCM showed that the percentage of cells in G2/M phase was significanty more in R and D+R groups than in Ci and Cd groups (68.00±1.65,54.27±5.74,17.60±0.80,14.86±1.23, t=47.70,P=0.000; t=11.63, P=0.000), and also significantly different between R group and D + R group (t=3.99, P= 0.020). The apoptosis rate was higher in R and D + R groups than Ci and Cd groups(4.83±0.97,9.50± 1.35,1.33±0.86 and 2.28±0.42,t=4.67,P=0.010;t=8.81, P=0.000), D + R group than R group(t =4.85,P=0.010). Conclusions Celecoxib can markedly inhibit the growth and induce apoptosis in CNE-2 cells,which may depend on COX-2 pathway. Celeeoxib potently enhances the radiosensitivity of CNE-2 cells,which may due to the repair inhibit of radiation-induced DNA damage, inhibit of cell proliferation,and enhancement of cell apoptosis after irradiation.     

枸椽酸氢钾钠治疗输尿管小结石的临床研究

目的:探讨枸椽酸氢钾钠治疗输尿管小结石的临床价值.方法:将63例伴肾绞痛的输尿管小结石(＜0.6 cm)患者分为用药组31例和对照组32例,均采用解痉、输液、利尿治疗,用药组加口服枸椽酸氢钾钠颗粒,并记录排石情况,排出结石的大小.结果:在观察期内用药组28例排出结石,有效率90.3%,对照组22例排出结石,有效率68.8%,两者存在统计学差异(P＜0.05),排出结石的时间用药组(3.3±2.1)d,对照组(4.1±2.3)d,存在统计学差异(P＜0.05),排出结石大小比B超测得均小,用药组有统计学差异(P＜0.05),对照组无统计学意义(P＞0.05),用药组未出现药物不良反应.结论:枸椽酸氢钾钠能有效缩小输尿管结石,加快结石的排出,是内科保守治疗输尿管小结石安全有效的辅助治疗药物.